Evaluating ShockPulse-10 for treating coronary artery calcification

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory, multicenter clinical trial aims to assess the safety and performance of ShockPulse-10 in patients with significant coronary artery calcification. Conducted at eight sites in China, the study will enroll up to 205 participants who are scheduled for stent procedures. Participants will be followed for 180 days post-procedure to evaluate clinical outcomes, including procedure success defined by successful stent implantation and the occurrence of major adverse cardiac events. The trial focuses on patients with specific criteria related to coronary artery disease and calcification.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Patient is ≥ 18 years of age;
2. Patients with significant coronary artery disease (including stable or unstable angina and asymptomatic myocardial ischemia) who are suitable for PCI treatment;
3. A single newly developed stenosis of the target vessel, which is the left anterior descending artery, right coronary artery, or circumflex artery (or its branches), with stenosis degree ≥70% or ≥50% (Visually inspect ) and accompanied by evidence of ischemia;
4. The target lesion is a primary, in situ coronary artery lesion;
5. The reference vessel diameter for the target lesion is 2.0-4.0mm, and the length of the target lesion is ≤40mm (Visually inspect);
6. Visual assessment indicates that the lesion site can accommodate the passage of a pre-dilator or trial instrument through the lesion;
7. The target lesion site has moderate to severe calcification (meeting one of the following conditions)：

   ① Angiography: Moderate calcification :clearer and more easily visible high-density shadows during cardiac pulsation; Severe calcification :clear high-density shadows both during and at rest;

   ② IVUS calcium score ≥2 points for superficial intimal, deep medial, and mixed calcification;
8. TIMI grade 3 in target vessel before registration (pre-dilation is allowed);

Key exclusion Criteria:

1. Left ventricular ejection fraction \< 40%；
2. NYHA class III or IV heart failure；
3. Patients with single coronary artery supply;
4. Patients with evidence of dissection at the site of the lesion on imaging;
5. The imaging suggests that the vascular pathway is tortuous, making it difficult for the pre-dilatation device to reach the target location or to be retrieved;
6. Patients with active systemic infections;
7. Patients with uncontrollable severe hypertension (systolic pressure \> 180 mmHg or diastolic pressure \> 110 mmHg);
8. Patients with coagulopathy, hypercoagulable state or significant bleeding tendency (hemoglobin \<10g/dL or platelet count \<80×10\^9/L);

Where it's running

• Beijing Anzhen Hosipital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: XIANTAO SONG, Dortor — Beijing Anzhen Hosipital
• Study coordinator: XIANTAO SONG, Dortor
• Email: Song0929@mail.ccmu.edu.cn
• Phone: 010-64412431

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-Pressure Cutting Balloon for Calcified Coronary Lesions in IVUS-Guided DES

  This trial tests whether using a high-pressure cutting balloon before placing an IVUS-guided drug-eluting stent helps optimize stent placement in people with calcified coronary blockages.

  Recruiting BrosMed Medical Co., Ltd · Xi'an, Shaanxi · NCT07835178

• Red grape juice and metabolism in men with coronary disease

  Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07777341

• Edoxaban vs. Apixaban in AF with CAD: Net Benefit

  This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.

  Recruiting Phase 4 Samsung Medical Center · Seoul · NCT07753200

• Revascularization of Calcified Coronary Arteries

  This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.

  Recruiting Aalborg University Hospital · Aalborg · NCT07724184

• OPN Balloon Use for Recanalization of Calcified Coronary Lesions

  This registry tests how the SIS-OPN balloon is used in real-world patients with calcified coronary disease who have undergone PCI in North America.

  Recruiting Minneapolis Heart Institute Foundation · Minneapolis, Minnesota · NCT07646444

• Pulse IVL to open calcified coronary vessels in CAD

  A small, early feasibility study tests the Pulse Intravascular Lithotripsy system in adults with coronary artery disease to see if it can safely open calcified arteries and improve vessel compliance.

  Recruiting at 4 sites Amplitude Vascular Systems, Inc. · Sydney, New South Wales and 3 other locations · NCT07510438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.